<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443130</url>
  </required_header>
  <id_info>
    <org_study_id>09-0112</org_study_id>
    <secondary_id>4R01AI104702-04</secondary_id>
    <nct_id>NCT01443130</nct_id>
  </id_info>
  <brief_title>Chloroquine for Malaria in Pregnancy</brief_title>
  <official_title>A Randomized, Controlled Clinical Trial of Chloroquine as Chemoprophylaxis Versus Intermittent Preventive Therapy to Prevent Malaria in Pregnancy in Malawi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test prevention strategies for pregnancy-related malaria.
      Researchers will compare different malaria treatments and treatment schedules which include
      chloroquine therapy (weekly doses versus being dosed twice during pregnancy for 3 days each
      time) to the standard practice of preventive treatment intervals in pregnancy (with the drug
      sulfadoxine-pyrimethamine given twice during pregnancy). Participants will include 900
      pregnant women, who will be assigned to one of three treatment groups. Blood samples will be
      collected at every visit before birth and any time the participant is ill to determine if
      malaria is present. Pregnant women will be monitored during pregnancy and newborns will be
      assessed at birth and followed until about 14 weeks. Participant involvement in the study is
      expected to last about 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In areas of high malaria endemicity, typical of much of sub-Saharan Africa, despite having
      achieved semi-immunity to malaria in adulthood, women become vulnerable to malaria infection
      during pregnancy, especially during their first or second pregnancy. They have increased
      rates of infection in the peripheral blood and high concentrations of parasites can be found
      in the placenta. On histological examination, mature asexual parasites, forms that are not
      usually detected in the peripheral blood, accumulate in the placenta. Pregnancy-specific
      variant surface antigens are responsible for the increased vulnerability of pregnant women to
      malaria because they are unrecognized by the immune systems of women who encounter them for
      the first time in their first pregnancy. In subsequent pregnancies, women develop immunity to
      these parasite surface antigens and the parasites are cleared by the host response.
      Plasmodium (P) falciparum infection during pregnancy has important health consequences for
      both pregnant women and their newborns. Adverse outcomes of pregnancy-associated malaria that
      have been documented in Malawi include maternal anemia, low birth weight (LBW), and increased
      infant mortality. The primary objective of the study is to compare weekly chloroquine
      prophylaxis and chloroquine intermittent preventative therapy (IPT) for malaria in pregnancy
      (IPTp) to the standard practice [IPTp with sulfadoxine-pyrimethamine (SP)] with respect to
      prevention of placental malaria. The secondary objectives are: to compare weekly chloroquine
      prophylaxis and chloroquine IPTp to the standard practice (IPTp with SP) with respect to
      prevention of malaria during pregnancy; to compare weekly chloroquine prophylaxis and
      chloroquine IPTp to the standard practice (IPTp with SP) with respect to prevention of the
      adverse maternal and newborn effects of pregnancy-associated malaria. The exploratory
      objective identify the vulnerable periods during pregnancy when malaria infection is more
      likely to cause placental infection, maternal anemia, and low infant birth weight. This is a
      randomized controlled trial to compare chloroquine as IPT or chloroquine as chemoprophylaxis
      to IPTp with SP. Women will be randomized after Screening and enrollment, and they begin the
      assigned treatment between Week 20 and Week 28 gestation. Specimens will be collected at
      every prenatal visit and any time the participant is ill to determine if malaria is present.
      Pregnant women will be monitored during pregnancy, and newborns will be assessed at birth and
      followed until they are approximately 14 weeks of age. Participants will be randomized to one
      of the following regimens: Chloroquine approximately 1,500 mg base over 3 days, twice during
      pregnancy (2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2); Chloroquine base 600
      mg (2 tablets) loading dose followed by 300 mg (1 tablet) orally once per week until
      delivery; SP 1500 mg/75 mg twice during pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Placental Malaria Infection Based on Histology</measure>
    <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
    <description>The placenta was collected at the time of delivery for examination by histology to determine malaria infection. Malaria infection was concluded if histology identified parasites or malaria pigment in the placental tissue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Placental Malaria by Placental Impression Smear</measure>
    <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of malaria infection in the placenta based on diagnosis by positive placental impression smear results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Maternal Anemia (Hemoglobin &lt; 10 Grams/Deciliter)</measure>
    <time_frame>From enrollment until delivery, approximately 12-36 weeks</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of anemia among maternal participants during pregnancy . Anemia is defined as having a hemoglobin value less than 10 grams/deciliter (gm/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Maternal Severe Anemia (Hemoglobin &lt; 7gm/dl)</measure>
    <time_frame>From enrollment until delivery, approximately 12-36 weeks</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of severe anemia among maternal participants during pregnancy. Severe anemia is defined as having a hemoglobin value less than 7 gm/dl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stillbirth</measure>
    <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was stillbirth, defined as an infant born without any signs of life at 28 weeks or greater of gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Miscarriage</measure>
    <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was miscarriage, defined as an infant delivered without any signs of life at less than 28 weeks of gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Preterm Delivery</measure>
    <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was preterm delivery, defined as delivery less than 37 weeks of gestation. The outcome of the delivery was not considered, and could have been live birth, stillbirth, or miscarriage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Mortality Rate to 14 Weeks of Age</measure>
    <time_frame>For 14 weeks after delivery.</time_frame>
    <description>Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants who died within 14 weeks of delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Low Birth Weight (LBW) (Birthweight &lt; 2500 Grams)</measure>
    <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of infants whose birthweight was less than 2500 grams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Intrauterine Growth Restriction (IUGR)</measure>
    <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
    <description>Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants with IUGR at delivery. IUGR is defined as weight below the 10th percentile for gestational age based on the World Health Organization (WHO) fetal growth curve. This classification is supported by literature resulting from the INTERGROWTH-21st Project; José Villar.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Active Placental Malaria Infection</measure>
    <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of placental malaria infections in maternal subjects diagnosed by the presence of parasites and/or pigment on histological section or molecular evidence of infection (PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Malaria Infection, All Species.</measure>
    <time_frame>Enrollment to delivery (approximately 12-36 weeks)</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of malaria infection episodes measured by positive parasitemia in maternal subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clinical Malaria, All Species</measure>
    <time_frame>Enrollment to delivery (approximately 12-36 weeks)</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. Clinical malaria is defined as malaria infection at any parasite density with associated symptoms including at least one of the following: objective fever measured at the clinic, history of fever in the past 48 hours or other symptoms in the last 48 hours including: headache, myalgia, vomiting, or weakness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Infection in the Fetal Circulation</measure>
    <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
    <description>Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of positive for malaria cord blood smear and cord PCR results in maternal subjects based on the results of the thick smear and PCR from the cord blood sample.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">900</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Chloroquine IPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 subjects to receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) will be administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 subjects to receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP IPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 subjects to receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.</description>
    <arm_group_label>Chloroquine IPT</arm_group_label>
    <arm_group_label>Chloroquine Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfadoxine-pyrimethamine</intervention_name>
    <description>Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.</description>
    <arm_group_label>SP IPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women who present to the Ndirande Antenatal Clinic (ANC) and meet the following inclusion
        criteria will be enrolled in the study: -Before the end of 27th week of gestation -First or
        second pregnancy -Anticipate remaining in Blantyre until 14 weeks after delivery -Agree to
        deliver at the Ndirande Health Centre or Queen Elizabeth Central Hospital (QECH) -Provision
        of informed consent

        Exclusion Criteria:

        -Chronic use (&gt;14 days) of any medication with antimalarial or antifolate activity -Human
        immunodeficiency virus (HIV) infection -Known high-risk pregnancy requiring regular
        supervision of an obstetrician -Allergy to any of the study drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Blantyre Malaria Project - Queen Elizabeth Central Hospital</name>
      <address>
        <city>Blantryre</city>
        <state>Blantyre</state>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <results_first_submitted>October 1, 2015</results_first_submitted>
  <results_first_submitted_qc>October 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 29, 2015</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria,Malawi,pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were pregnant women in their first or second pregnancy recruited during presentation at the Ndirande Antenatal Clinic (ANC) at the Ndirande Health Centre, enrolled between 22 February 2012 and 16 May 2014.</recruitment_details>
      <pre_assignment_details>The infants born to these participants were also enrolled in the study to be assessed at birth and followed to 14 weeks. The infants are reported here as separate arms of the study, grouped by the study product given to the mother.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Maternal Chloroquine Prophylaxis</title>
          <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
        </group>
        <group group_id="P2">
          <title>Maternal Chloroquine IPT</title>
          <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Maternal SP IPT</title>
          <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Infant Chloroquine Prophylaxis</title>
          <description>Infants born to maternal participants who received chloroquine prophylaxis.</description>
        </group>
        <group group_id="P5">
          <title>Infant Chloroquine IPT</title>
          <description>Infants born to maternal participants who received chloroquine IPT.</description>
        </group>
        <group group_id="P6">
          <title>Infant SP IPT</title>
          <description>Infants born to maternal participants who received SP IPT.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="300"/>
                <participants group_id="P3" count="300"/>
                <participants group_id="P4" count="270"/>
                <participants group_id="P5" count="274"/>
                <participants group_id="P6" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="223"/>
                <participants group_id="P4" count="231"/>
                <participants group_id="P5" count="230"/>
                <participants group_id="P6" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="44"/>
                <participants group_id="P6" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death of Subject's Infant</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants enrolled in the study are included in the baseline analysis population, with the exception of the age continuous for all groups, which is limited to the maternal participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Maternal Chloroquine Prophylaxis</title>
          <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
        </group>
        <group group_id="B2">
          <title>Maternal Chloroquine IPT</title>
          <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Maternal SP IPT</title>
          <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Infant Chloroquine Prophylaxis</title>
          <description>Infants born to maternal participants who received chloroquine prophylaxis.</description>
        </group>
        <group group_id="B5">
          <title>Infant Chloroquine IPT</title>
          <description>Infants born to maternal participants who received chloroquine IPT.</description>
        </group>
        <group group_id="B6">
          <title>Infant SP IPT</title>
          <description>Infants born to maternal participants who received SP IPT.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="300"/>
            <count group_id="B2" value="300"/>
            <count group_id="B3" value="300"/>
            <count group_id="B4" value="270"/>
            <count group_id="B5" value="274"/>
            <count group_id="B6" value="259"/>
            <count group_id="B7" value="1703"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="270"/>
                    <measurement group_id="B5" value="274"/>
                    <measurement group_id="B6" value="259"/>
                    <measurement group_id="B7" value="1073"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="210"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="630"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.40" spread="3.59"/>
                    <measurement group_id="B2" value="20.67" spread="3.24"/>
                    <measurement group_id="B3" value="20.44" spread="3.14"/>
                    <measurement group_id="B4" value="0" spread="0"/>
                    <measurement group_id="B5" value="0" spread="0"/>
                    <measurement group_id="B6" value="0" spread="0"/>
                    <measurement group_id="B7" value="20.50" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="300"/>
                    <measurement group_id="B4" value="133"/>
                    <measurement group_id="B5" value="143"/>
                    <measurement group_id="B6" value="136"/>
                    <measurement group_id="B7" value="1312"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="137"/>
                    <measurement group_id="B5" value="131"/>
                    <measurement group_id="B6" value="123"/>
                    <measurement group_id="B7" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Malawi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="300"/>
                    <measurement group_id="B4" value="270"/>
                    <measurement group_id="B5" value="274"/>
                    <measurement group_id="B6" value="259"/>
                    <measurement group_id="B7" value="1703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Placental Malaria Infection Based on Histology</title>
        <description>The placenta was collected at the time of delivery for examination by histology to determine malaria infection. Malaria infection was concluded if histology identified parasites or malaria pigment in the placental tissue.</description>
        <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
        <population>All participants from whom the placental histopathology slides collected at the time of delivery were reviewed are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Placental Malaria Infection Based on Histology</title>
          <description>The placenta was collected at the time of delivery for examination by histology to determine malaria infection. Malaria infection was concluded if histology identified parasites or malaria pigment in the placental tissue.</description>
          <population>All participants from whom the placental histopathology slides collected at the time of delivery were reviewed are included in the analysis.</population>
          <units>percentage of pregnancies</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="253"/>
                <count group_id="O3" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.58" lower_limit="7.52" upper_limit="16.80"/>
                    <measurement group_id="O2" value="15.42" lower_limit="10.67" upper_limit="21.21"/>
                    <measurement group_id="O3" value="15.42" lower_limit="10.67" upper_limit="21.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of placental malaria infection based on histology is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2441</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of placental malaria infection based on histology is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Placental Malaria by Placental Impression Smear</title>
        <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of malaria infection in the placenta based on diagnosis by positive placental impression smear results.</description>
        <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
        <population>The analysis population includes all maternal participants whose pregnancies were followed to delivery and from whom a placenta was collected and an impression smear performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Placental Malaria by Placental Impression Smear</title>
          <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of malaria infection in the placenta based on diagnosis by positive placental impression smear results.</description>
          <population>The analysis population includes all maternal participants whose pregnancies were followed to delivery and from whom a placenta was collected and an impression smear performed.</population>
          <units>percentage of placentas</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="254"/>
                <count group_id="O3" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="1.68"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="1.71"/>
                    <measurement group_id="O3" value="0.40" lower_limit="0.00" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of malaria by placental impression smear is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4941</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of malaria by placental impression smear is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4990</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Maternal Anemia (Hemoglobin &lt; 10 Grams/Deciliter)</title>
        <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of anemia among maternal participants during pregnancy . Anemia is defined as having a hemoglobin value less than 10 grams/deciliter (gm/dL).</description>
        <time_frame>From enrollment until delivery, approximately 12-36 weeks</time_frame>
        <population>The analysis population includes all maternal participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Maternal Anemia (Hemoglobin &lt; 10 Grams/Deciliter)</title>
          <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of anemia among maternal participants during pregnancy . Anemia is defined as having a hemoglobin value less than 10 grams/deciliter (gm/dL).</description>
          <population>The analysis population includes all maternal participants.</population>
          <units>percentage of maternal participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="13.58" upper_limit="23.89"/>
                    <measurement group_id="O2" value="23.7" lower_limit="18.36" upper_limit="29.64"/>
                    <measurement group_id="O3" value="22.0" lower_limit="16.85" upper_limit="27.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of maternal anemia is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3089</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of maternal anemia is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6973</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Maternal Severe Anemia (Hemoglobin &lt; 7gm/dl)</title>
        <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of severe anemia among maternal participants during pregnancy. Severe anemia is defined as having a hemoglobin value less than 7 gm/dl.</description>
        <time_frame>From enrollment until delivery, approximately 12-36 weeks</time_frame>
        <population>The analysis population includes all maternal participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Maternal Severe Anemia (Hemoglobin &lt; 7gm/dl)</title>
          <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of severe anemia among maternal participants during pregnancy. Severe anemia is defined as having a hemoglobin value less than 7 gm/dl.</description>
          <population>The analysis population includes all maternal participants.</population>
          <units>percentage of maternal participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="1.45"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.00" upper_limit="2.11"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.00" upper_limit="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of maternal severe anemia is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of maternal severe anemia is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Stillbirth</title>
        <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was stillbirth, defined as an infant born without any signs of life at 28 weeks or greater of gestation.</description>
        <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
        <population>The analysis population includes all participants whose pregnancies were followed to delivery.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Stillbirth</title>
          <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was stillbirth, defined as an infant born without any signs of life at 28 weeks or greater of gestation.</description>
          <population>The analysis population includes all participants whose pregnancies were followed to delivery.</population>
          <units>percentage of deliveries</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.17" upper_limit="3.54"/>
                    <measurement group_id="O2" value="0.37" lower_limit="0.00" upper_limit="2.31"/>
                    <measurement group_id="O3" value="1.90" lower_limit="0.52" upper_limit="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of stillbirth is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4979</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of stillbirth is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1166</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Miscarriage</title>
        <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was miscarriage, defined as an infant delivered without any signs of life at less than 28 weeks of gestation.</description>
        <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
        <population>The analysis population includes all maternal participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Miscarriage</title>
          <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was miscarriage, defined as an infant delivered without any signs of life at less than 28 weeks of gestation.</description>
          <population>The analysis population includes all maternal participants.</population>
          <units>percentage of pregnancies</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0" upper_limit="2.11"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.06" upper_limit="2.68"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.16" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of miscarriage is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6237</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of miscarriage is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Preterm Delivery</title>
        <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was preterm delivery, defined as delivery less than 37 weeks of gestation. The outcome of the delivery was not considered, and could have been live birth, stillbirth, or miscarriage.</description>
        <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
        <population>The analysis population includes all participants whose pregnancies were followed to delivery.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Preterm Delivery</title>
          <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was preterm delivery, defined as delivery less than 37 weeks of gestation. The outcome of the delivery was not considered, and could have been live birth, stillbirth, or miscarriage.</description>
          <population>The analysis population includes all participants whose pregnancies were followed to delivery.</population>
          <units>percentage of deliveries</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.46" lower_limit="5.08" upper_limit="13.02"/>
                    <measurement group_id="O2" value="9.89" lower_limit="6.23" upper_limit="14.69"/>
                    <measurement group_id="O3" value="6.84" lower_limit="3.80" upper_limit="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of preterm delivery is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5187</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of preterm delivery is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2163</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant Mortality Rate to 14 Weeks of Age</title>
        <description>Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants who died within 14 weeks of delivery.</description>
        <time_frame>For 14 weeks after delivery.</time_frame>
        <population>The analysis population includes all enrolled infants.</population>
        <group_list>
          <group group_id="O1">
            <title>Infant Chloroquine Prophylaxis</title>
            <description>Infants born to maternal participants who received chloroquine prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Infant Chloroquine IPT</title>
            <description>Infants born to maternal participants who received chloroquine IPT.</description>
          </group>
          <group group_id="O3">
            <title>Infant SP IPT</title>
            <description>Infants born to maternal participants who received SP IPT.</description>
          </group>
        </group_list>
        <measure>
          <title>Infant Mortality Rate to 14 Weeks of Age</title>
          <description>Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants who died within 14 weeks of delivery.</description>
          <population>The analysis population includes all enrolled infants.</population>
          <units>percentage of infants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" lower_limit="0.70" upper_limit="5.18"/>
                    <measurement group_id="O2" value="3.65" lower_limit="1.58" upper_limit="7.07"/>
                    <measurement group_id="O3" value="3.09" lower_limit="1.18" upper_limit="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of infant mortality within 14 weeks of delivery is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5959</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of infant mortality within 14 weeks of delivery is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8127</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Low Birth Weight (LBW) (Birthweight &lt; 2500 Grams)</title>
        <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of infants whose birthweight was less than 2500 grams.</description>
        <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
        <population>The analysis population includes all infants born alive with weight data collected at birth.</population>
        <group_list>
          <group group_id="O1">
            <title>Infant Chloroquine Prophylaxis</title>
            <description>Infants born to maternal participants who received chloroquine prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Infant Chloroquine IPT</title>
            <description>Infants born to maternal participants who received chloroquine IPT.</description>
          </group>
          <group group_id="O3">
            <title>Infant SP IPT</title>
            <description>Infants born to maternal participants who received SP IPT.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Low Birth Weight (LBW) (Birthweight &lt; 2500 Grams)</title>
          <description>Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of infants whose birthweight was less than 2500 grams.</description>
          <population>The analysis population includes all infants born alive with weight data collected at birth.</population>
          <units>percentage of infants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.59" lower_limit="10.91" upper_limit="21.28"/>
                    <measurement group_id="O2" value="10.98" lower_limit="7.06" upper_limit="16.05"/>
                    <measurement group_id="O3" value="12.11" lower_limit="7.93" upper_limit="17.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of low birth weight is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2566</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of low birth weight is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7839</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Intrauterine Growth Restriction (IUGR)</title>
        <description>Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants with IUGR at delivery. IUGR is defined as weight below the 10th percentile for gestational age based on the World Health Organization (WHO) fetal growth curve. This classification is supported by literature resulting from the INTERGROWTH-21st Project; José Villar.</description>
        <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
        <population>This analysis population includes all infants with weight captured at delivery and with mothers having reported gestational age at delivery.</population>
        <group_list>
          <group group_id="O1">
            <title>Infant Chloroquine Prophylaxis</title>
            <description>Infants born to maternal participants who received chloroquine prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Infant Chloroquine IPT</title>
            <description>Infants born to maternal participants who received chloroquine IPT.</description>
          </group>
          <group group_id="O3">
            <title>Infant SP IPT</title>
            <description>Infants born to maternal participants who received SP IPT.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Intrauterine Growth Restriction (IUGR)</title>
          <description>Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants with IUGR at delivery. IUGR is defined as weight below the 10th percentile for gestational age based on the World Health Organization (WHO) fetal growth curve. This classification is supported by literature resulting from the INTERGROWTH-21st Project; José Villar.</description>
          <population>This analysis population includes all infants with weight captured at delivery and with mothers having reported gestational age at delivery.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.54" lower_limit="11.70" upper_limit="22.37"/>
                    <measurement group_id="O2" value="18.01" lower_limit="12.98" upper_limit="23.98"/>
                    <measurement group_id="O3" value="20.80" lower_limit="15.32" upper_limit="27.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of intrauterine growth restriction is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2553</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of intrauterine growth restriction is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4354</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Active Placental Malaria Infection</title>
        <description>Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of placental malaria infections in maternal subjects diagnosed by the presence of parasites and/or pigment on histological section or molecular evidence of infection (PCR).</description>
        <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
        <population>This analysis population includes all maternal subjects with placental slides reviewed and PCR results obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Active Placental Malaria Infection</title>
          <description>Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of placental malaria infections in maternal subjects diagnosed by the presence of parasites and/or pigment on histological section or molecular evidence of infection (PCR).</description>
          <population>This analysis population includes all maternal subjects with placental slides reviewed and PCR results obtained.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="253"/>
                <count group_id="O3" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" lower_limit="1.18" upper_limit="6.46"/>
                    <measurement group_id="O2" value="3.16" lower_limit="1.21" upper_limit="6.61"/>
                    <measurement group_id="O3" value="4.74" lower_limit="2.24" upper_limit="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of active placental malaria infection is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3690</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of active placental malaria infection is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4947</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Malaria Infection, All Species.</title>
        <description>Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of malaria infection episodes measured by positive parasitemia in maternal subjects.</description>
        <time_frame>Enrollment to delivery (approximately 12-36 weeks)</time_frame>
        <population>The analysis population includes all maternal participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Malaria Infection, All Species.</title>
          <description>Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of malaria infection episodes measured by positive parasitemia in maternal subjects.</description>
          <population>The analysis population includes all maternal participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="0.06" upper_limit="2.68"/>
                    <measurement group_id="O2" value="1.67" lower_limit="0.45" upper_limit="4.20"/>
                    <measurement group_id="O3" value="3.00" lower_limit="1.22" upper_limit="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of malaria infection (all species) measured by positive parasitemia is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0630</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of malaria infection (all species) measured by positive parasitemia is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4184</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Clinical Malaria, All Species</title>
        <description>Maternal participants were followed to outcome of the pregnancy. Clinical malaria is defined as malaria infection at any parasite density with associated symptoms including at least one of the following: objective fever measured at the clinic, history of fever in the past 48 hours or other symptoms in the last 48 hours including: headache, myalgia, vomiting, or weakness.</description>
        <time_frame>Enrollment to delivery (approximately 12-36 weeks)</time_frame>
        <population>The analysis population includes all maternal participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinical Malaria, All Species</title>
          <description>Maternal participants were followed to outcome of the pregnancy. Clinical malaria is defined as malaria infection at any parasite density with associated symptoms including at least one of the following: objective fever measured at the clinic, history of fever in the past 48 hours or other symptoms in the last 48 hours including: headache, myalgia, vomiting, or weakness.</description>
          <population>The analysis population includes all maternal participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="0.53" upper_limit="4.89"/>
                    <measurement group_id="O2" value="1.33" lower_limit="0.97" upper_limit="6.09"/>
                    <measurement group_id="O3" value="3.00" lower_limit="0.07" upper_limit="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of clinical malaria (all species) is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0268</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Cox proportional hazards</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of clinical malaria (all species) is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1646</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Cox proportional hazards</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Infection in the Fetal Circulation</title>
        <description>Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of positive for malaria cord blood smear and cord PCR results in maternal subjects based on the results of the thick smear and PCR from the cord blood sample.</description>
        <time_frame>At delivery: Approximately 12-36 weeks after enrollment</time_frame>
        <population>The analysis population includes all maternal participants with cord blood smears and cord PCR results obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Chloroquine Prophylaxis</title>
            <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Chloroquine IPT</title>
            <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Maternal SP IPT</title>
            <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Infection in the Fetal Circulation</title>
          <description>Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of positive for malaria cord blood smear and cord PCR results in maternal subjects based on the results of the thick smear and PCR from the cord blood sample.</description>
          <population>The analysis population includes all maternal participants with cord blood smears and cord PCR results obtained.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" lower_limit="0.53" upper_limit="4.89"/>
                    <measurement group_id="O2" value="2.78" lower_limit="0.97" upper_limit="6.09"/>
                    <measurement group_id="O3" value="0.80" lower_limit="0.07" upper_limit="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of infection in the fetal circulation is identical between subjects receiving maternal chloroquine prophylaxis vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4501</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the incidence of infection in the fetal circulation is identical between subjects receiving maternal chloroquine IPT vs. maternal SP IPT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1758</p_value>
            <p_value_desc>A Bonferroni correction was used due to multiple comparisons. Comparisons are statistically significant if the two-sided p-value is ≤ 0.05/2=0.025.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events and serious adverse events were collected after the administration of the first dose of study drug throughout the duration of the follow-up period (approximately 14 weeks following delivery).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Maternal Chloroquine Prophylaxis</title>
          <description>Maternal participants receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week until delivery.</description>
        </group>
        <group group_id="E2">
          <title>Maternal Chloroquine IPT</title>
          <description>Maternal participants receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Maternal SP IPT</title>
          <description>Maternal participants receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Infant Chloroquine Prophylaxis</title>
          <description>Infants born to maternal participants who received chloroquine prophylaxis.</description>
        </group>
        <group group_id="E5">
          <title>Infant Chloroquine IPT</title>
          <description>Infants born to maternal participants who received chloroquine IPT.</description>
        </group>
        <group group_id="E6">
          <title>Infant SP IPT</title>
          <description>Infants born to maternal participants who received SP IPT.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="270"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="274"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Accessory auricle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Laryngomalacia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Polydactyly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="270"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Umbilical cord haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Postpartum sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="270"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Group B streptococcus neonatal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="270"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="274"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Feeding disorder neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Marasmus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Haemorrhage in pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Preterm premature rupture of membranes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Prolonged rupture of membranes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Uterine contractions during pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Low birth weight baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="270"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Brief psychotic disorder, with postpartum onset</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="270"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Neonatal aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Transient tachypnoea of the newborn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Melanosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Vacuum extractor delivery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="255" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="234" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="195" subjects_at_risk="270"/>
                <counts group_id="E5" subjects_affected="186" subjects_at_risk="274"/>
                <counts group_id="E6" subjects_affected="171" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="300"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="300"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="270"/>
                <counts group_id="E5" events="28" subjects_affected="27" subjects_at_risk="274"/>
                <counts group_id="E6" events="17" subjects_affected="17" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="92" subjects_affected="78" subjects_at_risk="300"/>
                <counts group_id="E2" events="90" subjects_affected="73" subjects_at_risk="300"/>
                <counts group_id="E3" events="77" subjects_affected="62" subjects_at_risk="300"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="270"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="39" subjects_affected="36" subjects_at_risk="300"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="300"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="270"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="300"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="37" subjects_affected="32" subjects_at_risk="300"/>
                <counts group_id="E2" events="75" subjects_affected="63" subjects_at_risk="300"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="270"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="300"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="300"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E4" events="19" subjects_affected="18" subjects_at_risk="270"/>
                <counts group_id="E5" events="15" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="300"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="300"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="300"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="270"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="300"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="113" subjects_affected="90" subjects_at_risk="300"/>
                <counts group_id="E2" events="70" subjects_affected="65" subjects_at_risk="300"/>
                <counts group_id="E3" events="82" subjects_affected="73" subjects_at_risk="300"/>
                <counts group_id="E4" events="172" subjects_affected="136" subjects_at_risk="270"/>
                <counts group_id="E5" events="154" subjects_affected="124" subjects_at_risk="274"/>
                <counts group_id="E6" events="152" subjects_affected="118" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="300"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="300"/>
                <counts group_id="E3" events="28" subjects_affected="27" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="300"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="300"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="270"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="274"/>
                <counts group_id="E6" events="18" subjects_affected="17" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="270"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E6" events="15" subjects_affected="14" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="300"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="300"/>
                <counts group_id="E4" events="19" subjects_affected="18" subjects_at_risk="270"/>
                <counts group_id="E5" events="19" subjects_affected="19" subjects_at_risk="274"/>
                <counts group_id="E6" events="18" subjects_affected="18" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="270"/>
                <counts group_id="E5" events="15" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="300"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="270"/>
                <counts group_id="E5" events="31" subjects_affected="29" subjects_at_risk="274"/>
                <counts group_id="E6" events="18" subjects_affected="17" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="300"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="300"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="270"/>
                <counts group_id="E5" events="16" subjects_affected="16" subjects_at_risk="274"/>
                <counts group_id="E6" events="13" subjects_affected="12" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" events="25" subjects_affected="22" subjects_at_risk="270"/>
                <counts group_id="E5" events="15" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E6" events="19" subjects_affected="19" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="300"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="300"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="88" subjects_affected="79" subjects_at_risk="300"/>
                <counts group_id="E2" events="95" subjects_affected="75" subjects_at_risk="300"/>
                <counts group_id="E3" events="70" subjects_affected="56" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E2" events="75" subjects_affected="62" subjects_at_risk="300"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="113" subjects_affected="88" subjects_at_risk="300"/>
                <counts group_id="E2" events="96" subjects_affected="76" subjects_at_risk="300"/>
                <counts group_id="E3" events="89" subjects_affected="76" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="300"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="300"/>
                <counts group_id="E3" events="27" subjects_affected="26" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Prolonged labour</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="300"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="300"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="300"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="300"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="300"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The observed placental malaria rate was lower than expected causing the study to be under powered. After review of a futility analysis, the Sponsor and DSMB recommended allowing the study to conclude as planned and not to increase the sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Miriam K. Laufer, MD, MPH</name_or_title>
      <organization>University of Maryland School of Medicine</organization>
      <phone>410-706-5333</phone>
      <email>mlaufer@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

